NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

ABIVAX Société Anonyme (ABVX) Stock Analysis

ABIVAX Société Anonyme (ABVX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ABVX

$93.49

+$0.90 (+0.97%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ABVX with… →

ABVX Key Statistics

As of Oct 21, 2026
Trading
Open
$93.86
Previous Close
$92.59
Day's Range
93.05–96.39
52-Week Range
69.81–148.83
Volume
947.94K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.23
Valuation
Market Cap
$8.16B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1,747.86
EPS (ttm)Profit attributable to each share over the last twelve months.
−6.08
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$336.10M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
87.27M
1-Year Return
+1.99%
Dividend and dates
Avg Volume
1.13M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ABVX closed at $93.49, +1.99% over 1 year.

ABIVAX Société Anonyme (ABVX) has a market capitalization of $8.16B.

In fiscal 2025, ABVX reported revenue of $0.00.

ABVX Stock Return by Calendar Year

ABIVAX Société Anonyme (ABVX) return since Oct 2023: what $10,000 became

1 year
$10,000 $10,199
+1.99%
3 years
$10,000 $112,639
+1,026.39%

If you had invested $10,000 in ABIVAX Société Anonyme (ABVX) at the close on October 20, 2023, the earliest close on record here, it would have been worth $112,639 at the close on October 21, 2026: +1,026.39% in total, +124.16% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−30.67%
2025+1,742.28%
2024−31.59%
2023 (partial year)+28.92%

As of October 21, 2026.

ABVX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$336.10M—
2024$0.00−$176.24M—
2023$0.00−$147.74M—
2022$0.00−$60.74M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$246.06M−$336.10M—
2024$0.00—−$172.98M−$176.24M—
2023$0.00—−$127.38M−$147.74M—
2022$0.00−$50.76M−$51.21M−$60.74M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ABVX Valuation vs Biotechnology Median

Median of 608 stocks
MetricABVXBiotechnology medianvs median
P/S ratio1,747.8613.30131.4x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ABIVAX Société Anonyme (ABVX) is capitalised at $8.16B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 98.

The 52-week range on file runs from $69.81 to $148.83. ABVX last closed at $93.49 on October 21, 2026. That is +$0.90 (+0.97%) against the previous close. The latest close sits 33.92% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $336.10M. Trailing earnings per share are −6.08.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 1,747.86. On price-to-sales that is 131.4 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is −0.23. Annualized volatility over the trailing 3 years is 346.09%. Over the trailing twelve months the total return is +1.99%. Across 3 years the annualized return works out at +124.16%.

Growth & Income

The record shows no dividend for ABVX.

So far in 2026 the total return is −30.67%. The strongest complete calendar year on file is 2025 at +1,742.28%; the weakest is 2024 at −31.59%.

Peer Comparison

ABIVAX Société Anonyme (ABVX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ABIVAX Société Anonyme ABVX $8.16B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. ABIVAX Société Anonyme has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Visit website →